微生物組市場規模、佔有率和成長分析（按產品、應用和地區分類）－2026-2033年產業預測

預計到 2024 年，全球微生物組市場規模將達到 10.7225 億美元，到 2025 年將成長至 12.6204 億美元，到 2033 年將成長至 46.4819 億美元，在預測期（2026-2033 年）內複合年成長率為 17.7%。

全球微生物組市場正經歷顯著成長，這主要得益於策略聯盟的激增，這些聯盟推動了微生物組治療方法，進一步推動了市場的發展勢頭。此外，可透過微生物組干預治療的疾病發生率不斷上升，也促進了對這些治療方法的需求成長。隨著人們對微生物組在健康和疾病中關鍵作用的認知不斷提高，具有影響力的治療方法的潛力正在醫療保健領域創造一個充滿活力且不斷發展的環境，為相關人員提供了眾多機會。

全球微生物組市場促進因素

全球微生物組市場的發展動力源自於人類腸道微生物組在提升藥物療效方面所扮演的關鍵角色。研究表明，維持體內微生物群落的平衡有助於控制多種健康狀況。微生物組與特定疾病之間的這種關聯為藥物研發和疫苗研發提供了創新機會。此外，這些微生物產生的豐富酶類表明其具有多種治療應用潛力，為發現新型治療方法開闢了新途徑，並凸顯了微生物組在推進醫療保健解決方案方面的重要性。

限制全球微生物組市場的因素

由於益生菌監管方面的挑戰，全球微生物組市場面臨許多阻礙。雖然益生菌尚未獲得美國食品藥物管理局 (FDA)核准作為活體生物治療產品，但它們可以合法地作為食品和膳食補充劑銷售。這個法規結構限制了聲稱具有治療、緩解或預防疾病功效的產品的銷售，並限制了其推廣。因此，這種限制可能會阻礙市場成長和消費者認知度，因為企業在遵守嚴格的廣告準則的同時，可能難以有效傳達益生菌的潛在益處。這種監管不確定性最終可能會影響微生物組領域的投資和創新。

全球微生物組市場趨勢

全球微生物組市場正呈現公私部門合作日益密切的顯著趨勢。這一成長勢頭主要由眾多創新小型公司推動，這些公司為尋求收購以加強其微生物組研究的主要相關人員提供了巨大的成長潛力。其目標是發現針對各種健康問題（包括肥胖症、肝病、糖尿病和代謝紊亂）的新藥和藥物標靶。主要企業正積極尋求策略夥伴關係和聯盟，尤其旨在透過強大的研發舉措來拓展產品系列，從而充分把握不斷成長的微生物組領域的潛力。

目錄

介紹

• 調查目標
• 調查範圍
• 定義

調查方法

• 資訊收集
• 二手資料和一手資料方法
• 市場規模預測
• 市場假設與限制

執行摘要

• 全球市場展望
• 供需趨勢分析
• 細分市場機會分析

市場動態與展望

• 市場規模
• 市場動態
  • 促進因素和機遇
  • 限制與挑戰
• 波特分析

關鍵市場考察

• 關鍵成功因素
• 競爭程度
• 關鍵投資機會
• 市場生態系統
• 市場吸引力指數（2025）
• PESTEL 分析
• 總體經濟指標
• 價值鏈分析
• 定價分析
• 監管環境
• 案例研究

全球微生物組市場規模（按產品和複合年成長率分類）（2026-2033 年）

• 益生菌
• 食物
• 益生元
• 特殊醫學食品
• 其他

全球微生物組市場規模（按應用及複合年成長率分類）（2026-2033 年）

• 治療藥物
• 診斷

全球微生物組市場規模及複合年成長率（2026-2033）

• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 德國
  • 西班牙
  • 法國
  • 英國
  • 義大利
  • 其他歐洲地區
• 亞太地區
  • 中國
  • 印度
  • 日本
  • 韓國
  • 亞太其他地區
• 拉丁美洲
  • 巴西
  • 其他拉丁美洲地區
• 中東和非洲
  • 海灣合作理事會國家
  • 南非
  • 其他中東和非洲地區

競爭資訊

• 前五大公司對比
• 主要企業的市場定位（2025 年）
• 主要市場參與者所採取的策略
• 近期市場趨勢
• 公司市佔率分析（2025 年）
• 主要企業公司簡介
  • 公司詳情
  • 產品系列分析
  • 依業務板塊進行公司股票分析
  • 2023-2025年營收年比比較

主要企業簡介

• Seres Therapeutics（USA）
• Ferring Pharmaceuticals（Switzerland）
• BiomeBank（Australia）
• Seed Health（USA）
• International Flavors & Fragrances Inc.（USA）
• Pendulum Therapeutics（USA）
• BioHM Health Inc.（USA）
• Actial Farmaceutica SRL（Italy）
• Optibiotix Health plc（UK）
• Resbiotic（USA）
• Infinant Health Inc.（USA）
• Biogaia AB（Sweden）
• Exegi Pharma LLC（USA）
• Vedanta Biosciences Inc.（USA）
• Enterome（France）
• Yakult（Japan）
• DuPont（USA）
• Metabiomics Corporation（USA）
• ViThera Pharmaceuticals（USA）
• Second Genome（USA）

結論與建議

Global Microbiome Market size was valued at USD 1072.25 Million in 2024 and is poised to grow from USD 1262.04 Million in 2025 to USD 4648.19 Million by 2033, growing at a CAGR of 17.7% during the forecast period (2026-2033).

The global microbiome market is experiencing significant growth driven by a surge in strategic partnerships aimed at advancing research and development in microbiome therapies. This collaborative approach enhances product innovation and development, positioning the market for novel treatment solutions. The anticipated rollout of groundbreaking medications, alongside an expanding portfolio of microbiome-based therapies, further fuels market momentum. Additionally, the rising incidence of diseases that microbiome interventions can address contributes to heightened demand for these therapies. As awareness of the microbiome's critical role in health and disease continues to grow, the potential for impactful therapies is creating a dynamic and evolving landscape in the healthcare sector, offering numerous opportunities for stakeholders.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Microbiome market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Microbiome Market Segments Analysis

Global Microbiome Market is segmented by Product, Application and region. Based on Product, the market is segmented into Probiotics, Foods, Prebiotics, Medical food and Others. Based on Application, the market is segmented into Therapeutics and Diagnostics. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Microbiome Market

The global microbiome market is driven by the crucial role human gut microbiomes play in enhancing the effectiveness of medicinal treatments. Research indicates that maintaining a balanced community of microorganisms within the body can aid in the management of various health conditions. This connection between microbial flora and specific diseases presents opportunities for innovation in drug development and vaccine creation. Additionally, the abundant enzymes produced by these microbes offer potential for diverse therapeutic applications, revealing new pathways for the discovery of novel treatments and highlighting the importance of microbiomes in advancing healthcare solutions.

Restraints in the Global Microbiome Market

The Global Microbiome market faces significant restraints due to regulatory challenges surrounding probiotics. Although FDA approval has not been granted for probiotics as live biotherapeutic products, they can still be legally marketed as part of food and dietary supplements. This regulatory framework limits their promotion, preventing these products from being marketed with claims of curing, mitigating, treating, or preventing diseases. Consequently, this restriction can hinder market growth and consumer perception, as companies may struggle to communicate the potential benefits of probiotics effectively while adhering to strict advertising guidelines. The lack of regulatory clarity can ultimately affect investment and innovation within the microbiome sector.

Market Trends of the Global Microbiome Market

The Global Microbiome market is witnessing a notable trend marked by an uptick in collaborations between public and private organizations. This surge is fueled by numerous innovative smaller enterprises that present high-growth prospects for larger stakeholders seeking acquisitions to enhance their research into microbiomes. The objective is to uncover novel drugs and drug targets for a diverse array of health conditions, including obesity, liver disorders, diabetes, and metabolic issues. Key players are increasingly engaging in strategic partnerships and alliances, particularly aimed at expanding their product portfolios through robust R&D initiatives, thereby positioning themselves to capitalize on the growing potential of the microbiome landscape.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2025
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis
• Regulatory Landscape
• Case Studies

Global Microbiome Market Size by Product & CAGR (2026-2033)

• Market Overview
• Probiotics
• Foods
• Prebiotics
• Medical food
• Others

Global Microbiome Market Size by Application & CAGR (2026-2033)

• Market Overview
• Therapeutics
• Diagnostics

Global Microbiome Market Size & CAGR (2026-2033)

• North America (Product, Application)
  • US
  • Canada
• Europe (Product, Application)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Product, Application)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Product, Application)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Product, Application)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2025
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2025
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2023-2025)

Key Company Profiles

• Seres Therapeutics (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Ferring Pharmaceuticals (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• BiomeBank (Australia)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Seed Health (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• International Flavors & Fragrances Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pendulum Therapeutics (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• BioHM Health Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Actial Farmaceutica SRL (Italy)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Optibiotix Health plc (UK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Resbiotic (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Infinant Health Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Biogaia AB (Sweden)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Exegi Pharma LLC (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Vedanta Biosciences Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Enterome (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Yakult (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• DuPont (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Metabiomics Corporation (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• ViThera Pharmaceuticals (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Second Genome (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations